Evolving strategies in the treatment of acute myocardial infarction in the community hospital setting

Journal of the American College of Cardiology

Volumn 42, Issue 4, 2003, Pages 642-645

  McKay, Raymond G ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; THIENO[2,3 B]PYRIDINE DERIVATIVE; THROMBIN INHIBITOR;

ACUTE HEART INFARCTION; BLEEDING; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EDITORIAL; EMERGENCY TREATMENT; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HEART MUSCLE REPERFUSION; HEART VENTRICLE FUNCTION; HUMAN; LONG TERM CARE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; STROKE; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0042731935     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00756-3     Document Type: Editorial

References (26)

1. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative overview. JAMA 1997;278:2093-8.
2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003;361:13-20.
3. Ryan TJ, Antman EM, Brooks NH, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
4. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941-7.
5. Angela BG, Gibson CM, Chin R, et al. Predictors of door-to-balloon delay in primary angioplasty. Am J Cardiol 2002;89:1156-61.
6. Andersen HR. The DANAMI-2 study. Presented at the Late Breaking Clinical Trials Sessions of the American College of Cardiology, March 20, 2002, Atlanta, Georgia.
7. Widimsky P, Groch L, Zelizko M, et al. Multicentre randomized trial comparing transport to primary angioplasty vs. immediate thrombolysis vs. combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory: the PRAGUE study. Eur Heart J 2000;21:823-31.
8. Grines CL, Westerhausen DR, Grines LL, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002;39:1713-9.
9. Boersma E, Maas AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5.
10. The GUSTO I Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
11. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated versus hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention trial. JAMA 1993;270:1211-6.
12. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction. Circulation 2001;104:636-41.
13. Aversano T, Aversano LT, Passamani E, et al., for the Atlantic C-PORT Investigators. Thrombolytic therapy vs. primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery. JAMA 2002;287:1943-51.
14. Gibson CM. A union in reperfusion: the concept of facilitated percutaneous coronary intervention. J Am Coll Cardiol 2000;36:1497-9.
15. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-8.
16. The TIMI Study Group. Comparison of invasive and conservative strategies following intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) II trial. N Engl J Med 1989;320:618-28.
17. Simoons ML, Arnold AER, Betriu A, et al. Thrombolysis with t-PA in acute myocardial infarction: no beneficial effects of immediate PTCA. Lancet 1988;1:197-203.
18. Llevadot J, Giugliano RP, Antman EM. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA 2001;286:442-9.
19. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-14.
20. The Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-3) Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.
21. Stone GW, Gines CL, Cox DA, et al. Primary angioplasty with or without abciximab compared to primary stenting with or without abciximab in acute myocardial infarction. N Engl J Med 2002;346:957-66.
22. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol 1999;34:1954-62.
23. Herrman HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED trial. J Am Coll Cardiol 2000;36:1489-96.
24. Schweiger MJ, Cannon CP, Murphy SA, et al. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol 2001;88:831-6.
25. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
26. Scheller B, Hennen B, Hammer B, et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003;42:634-41.